Friday, 6. November 2026 · Next update: 10:00 DE EN Log in
Cassandra.news
Tomorrow's news. Today.
💻 Technology · Next Month

Apple Inc. announces at its September 2026 event (September 9, 2026) a new Apple Watch (Series 12 or Ultra 3) featuring at least one new clinically validated health sensor function – e.g. non-invasive blood pressure measurement or continuous body temperature monitoring – (confirmed by Apple press release)

Miss ✦ AI-generated prediction Published on 22. August 2026 · Predicted for 9. September 2026 · Based on: Historical Cycle
Probability
40%

Apple has been researching non-invasive blood glucose and blood pressure monitoring for Apple Watch since 2020. Industry reports (Bloomberg, The Information, 2023–2025) cited 2025–2026 as a possible timeline for initial market release. Apple Watch Series 10 (2024) introduced FDA-approved sleep apnea detection; blood pressure measurement was widely discussed as the next logical step for Series 11/12. The September 2026 event (September 9) is already anchored by an open prediction for the iPhone 18 announcement — a new Apple Watch health feature is a separate, non-contradicting product attribute. Counter-argument: historical FDA approval delays for Apple health features. No bookmaker or Polymarket market available for this event.

Data basis for this prediction
  • Bloomberg/The Information: Apple Watch Blutdruckmessung in Entwicklung, Ziel 2025–2026 (Berichte 2023–2025)
  • Apple Watch Series 10 (2024): Schlafapnoe-Erkennung als jüngste FDA-zugelassene Health-Funktion (Apple Pressemitteilung, September 2024)
  • Apple September Event: iPhone-18-Ankündigung offen vorhergesagt – Apple Watch als Begleitprodukt bei jedem Herbst-Event üblich
Verdict: Miss
Apple kündigte am 9. September 2026 tatsächlich die Apple Watch Series 12 (und Ultra 4, nicht Ultra 3) an – das Kernereignis trat ein. Jedoch wurde KEINE neue klinisch validierte Gesundheitssensor-Funktion im Sinne der Vorhersage vorgestellt. Die Hauptneuheit war das sog. 'Health Sensing System' mit dem S11-Chip, das bestehende Sensoren verbessert: Herzfrequenzmessung 60× häufiger (alle 5 Sekunden statt bisher) und HRV-Messungen 24× häufiger – beides Steigerungen bestehender Features, keine neuen Sensormodalitäten. Nicht-invasive Blutdruckmessung wurde explizit NICHT angekündigt (MacObserver: 'Does the Apple Watch Series 12 Measure Blood Pressure? No'); die vorhandene Hypertonie-Benachrichtigung (Mustererkennung, keine direkte Blutdruckmessung) erhielt FDA-Freigabe bereits 2025 mit Series 11. Körpertemperatur-Überwachung als neue Feature ebenfalls nicht angekündigt. Quellen: Apple Newsroom (apple.com/newsroom/2026/09/introducing-apple-watch-series-12-with-the-all-new-health-sensing-system/), MacObserver, 9to5Mac (09.09.2026).
Related Predictions
💻 Technology ✦ AI

Palantir Technologies Inc. (NYSE: PLTR) closes above $185.00 per share on at least one trading day in November 2026 — confirmed by Nasdaq or Bloomberg by December 1, 2026

PLTR closed at $175.40 on November 4, 2026 (after-hours: $170.88, -2.58%; intraday high: $176.54; 52-week high: $212.94). Palantir clearly beat Q3-FY2026 EPS consensus: total revenue $2.313B, US Commercial revenue +148% YoY to $984M. The $185 threshold is +5.5% above the closing price or +8.3% above after-hours levels. Typical post-earnings 'sell the news' may weigh short-term, but the 52-week high of $212.94 confirms the level is reachable. NVIDIA earnings on November 18, 2026 could serve as a sector-wide catalyst. No direct Polymarket equivalent; own estimate: ~42%.

42%
Next Month · Predicted for 30. Nov 2026
💻 Technology ✦ AI

Cerebras Systems (NASDAQ: CBRS) closes below $100.00 per share on November 10, 2026 (confirmed by Nasdaq or Bloomberg by November 11, 2026)

CBRS trades at $109.18 (October 30, 2026) — already 61% below its all-time high of $279.72. The final and largest lockup expiration is scheduled for November 10, 2026: approximately 19.4 million shares are unlocked (of three tranches of 19.4M each). Prior lockup tranches have consistently weighed on the stock. Insiders have sold ~$394.6M in shares since the May 2026 IPO — zero insider purchases. A Culper Research short-seller report has triggered multiple investigations. A close below $100 requires a ~8.4% decline — plausible given the expected supply pressure on expiration day.

62%
Next Week · Predicted for 10. Nov 2026
💻 Technology ✦ AI

ARM Holdings plc (NASDAQ: ARM) beats Q2-FY2027 EPS consensus of $0.47 per share — earnings report November 4, 2026 after market close (confirmed by ARM Holdings Investor Relations or Bloomberg by November 5, 2026, 10:00 AM ET)

ARM Holdings reports Q2 FY2027 (July–September 2026) on November 4 after market close. EPS consensus: $0.47; revenue consensus ~$1.38B (Theta Research, Oct 29). ARM is the dominant CPU IP licensor for AI servers (Neoverse), smartphones (Apple A-series, Qualcomm), and edge devices — all three segments scaling strongly in 2026. ARM has beaten EPS consensus in each of the last four quarters, driven by AI infrastructure capex. No direct Polymarket contract; analogue: S&P 500 Q3 2026 beat rate ~71%. Key risks: export control escalation (UK/US vs. China), hyperscaler capex delays, or HBM4 demand plateau.

68%
Next Week · Predicted for 4. Nov 2026